- Home
- SLGL vs APRE Comparison
SLGL vs APRE Comparison
Compare SLGL & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLGL
- APRE
- Stock Information
- Founded
- SLGL 1997
- APRE 2006
- Country
- SLGL Israel
- APRE United States
- Employees
- SLGL N/A
- APRE N/A
- Industry
- SLGL Biotechnology: Pharmaceutical Preparations
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SLGL Health Care
- APRE Health Care
- Exchange
- SLGL Nasdaq
- APRE Nasdaq
- Market Cap
- SLGL 18.3M
- APRE 21.3M
- IPO Year
- SLGL 2018
- APRE 2019
- Fundamental
- Price
- SLGL $0.52
- APRE $2.90
- Analyst Decision
- SLGL Strong Buy
- APRE Strong Buy
- Analyst Count
- SLGL 2
- APRE 2
- Target Price
- SLGL $5.00
- APRE $15.50
- AVG Volume (30 Days)
- SLGL 68.5K
- APRE 13.3K
- Earning Date
- SLGL 11-15-2024
- APRE 11-07-2024
- Dividend Yield
- SLGL N/A
- APRE N/A
- EPS Growth
- SLGL N/A
- APRE N/A
- EPS
- SLGL N/A
- APRE N/A
- Revenue
- SLGL $11,707,000.00
- APRE $1,310,839.00
- Revenue This Year
- SLGL $457.85
- APRE $116.72
- Revenue Next Year
- SLGL N/A
- APRE N/A
- P/E Ratio
- SLGL N/A
- APRE N/A
- Revenue Growth
- SLGL 869.93
- APRE 130.31
- 52 Week Low
- SLGL $0.33
- APRE $2.15
- 52 Week High
- SLGL $1.58
- APRE $8.85
- Technical
- Relative Strength Index (RSI)
- SLGL 37.57
- APRE 35.16
- Support Level
- SLGL $0.40
- APRE $2.87
- Resistance Level
- SLGL $0.57
- APRE $3.35
- Average True Range (ATR)
- SLGL 0.06
- APRE 0.31
- MACD
- SLGL -0.01
- APRE -0.11
- Stochastic Oscillator
- SLGL 36.50
- APRE 5.84
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline consists of silica-based microencapsulation technology platform, and several generic product candidates across multiple indications.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.